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Abstract
Introduction Strict control of plasma glucose in diabetic and
non-diabetic patients has been shown to improve outcome in
several clinical settings. There is extensive evidence that
glucose can stimulate the production of pro-inflammatory
cytokines such as tumor necrosis factor (TNF)-α and IL-6, with
no effect on the anti-inflammatory cytokine IL-10. We
hypothesized that strict glucose regulation results in a change in
cytokine balance from a pro-inflammatory state to a more
balanced anti-inflammatory condition. In a randomized
controlled trial we studied the effect of strict glycemic control on
the local and systemic pro-inflammatory and anti-inflammatory
balance in non-diabetic patients undergoing elective coronary
artery bypass grafting with cardiopulmonary bypass.
Methods After surgery patients were randomly assigned to
intensive insulin therapy (blood glucose between 80 and 110
mg/dl) or conventional insulin therapy (blood glucose less than
200 mg/dl). At 0, 1, 2, 4, 8, 12, 16 and 24 hours after admission
to the intensive care unit, plasma samples and samples from the
mediastinal drains were obtained. We measured the
concentrations of the pro-inflammatory cytokines TNF-α and IL-
6 and the anti-inflammatory cytokine IL-10 by enzyme-linked
immunosorbent assay.
Results Both patient groups were comparable in
demographics, clinical characteristics and peri-operative data.
In the intensive treatment group, glucose levels were
significantly lower than in the conventionally treated group. No
differences were found between both groups in the
concentrations of TNF-α, IL-6 and IL-10 in plasma samples or in
fluid draining the mediastinal cavity. Levels of IL-6 and IL-10
were significantly higher in mediastinal fluid samples than in
plasma samples, suggesting a compartmentalized production of
cytokines.
Conclusion The protective effect of intensive insulin therapy in
patients after cardiac surgery with cardiopulmonary bypass is
not related to a change in cytokine balance from a pro-
inflammatory to an anti-inflammatory pattern. Systemic cytokine
levels are not representative of the local inflammatory response.
Introduction
Strict glycemic control is increasingly recognized as an impor-
tant goal in a broad spectrum of critically ill patients, even in
the absence of pre-existing diabetes. After myocardial infarc-
tion, stress hyperglycemia is associated with an increased risk
of in-hospital mortality in both diabetic and non-diabetic
patients and increases the risk of congestive heart failure or
cardiogenic shock in patients without diabetes [1]. The DIG-
AMI study demonstrated that rapid improvement of metabolic
control in diabetic patients with myocardial infarction improves
short-term and long-term outcome [2,3]. Intensive insulin ther-
apy is thought to increase the success rate of thrombolysis
and preserves myocardial function [4,5]. The recently pub-
lished DIGAMI 2 trial failed to support the hypothesis that insu-
lin treatment improves survival and morbidity in diabetic
patients after myocardial infarction, possibly because the tar-
get blood glucose levels in the treatment group were never
reached [6]. However, this trial confirmed that glucose is a
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strong and independent factor of long-term mortality in these
patients. In cardiac surgery patients, hyperglycemia was found
to be an independent post-operative risk factor for the devel-
opment of hyperlactatemia and associated with increased
morbidity and mortality [7,8]. A meta-analysis of all randomized
studies using glucose-insulin-potassium therapy in cardiac
surgery patients indicated that such therapy might considera-
bly improve post-operative recovery of contractile function and
reduce the incidence of atrial arrhythmias [9]. Some studies
even show a survival benefit [10]. In critically ill patients in a
surgical intensive care unit (ICU), maintenance of blood glu-
cose levels between 80 and 110 mg/dl resulted in a 42%
reduction in mortality compared with conventional treatment
aiming at blood glucose levels between 180 and 200 mg/dl
[11]. More than 60% of the patients in this study had also
recently had cardiac surgery.
How strict control of blood glucose reduces morbidity and
mortality is unknown, but the mechanism may be related either
to a direct effect of normalization of hyperglycemia or to the
concomitantly higher insulin levels. Post hoc multivariate logis-
tic regression analysis of the study by van den Berghe et al.
suggests that the lowered blood glucose level rather than the
insulin dose is related to the reduction in mortality [12,13]. In
this study [11] septic patients showed the largest reduction in
mortality, suggesting that strict glucose regulation might influ-
ence the inflammatory response.
Hyperglycemia has a strong impact on host defense. Acute,
short-term hyperglycemia affects all major components of
innate immunity [14]. Neutrophil activity is reduced, leading to
decreased chemotaxis, decreased phagocytosis, decreased
bacterial killing and overproduction of free radicals [15-17]. In
addition to changes in cellular function, other components of
the innate immune response contribute to the pro-inflamma-
tory state in hyperglycemia. In vitro, human monocytes show a
glucose-dependent increase in tumor necrosis factor (TNF)-α
and IL-6 production [18-20]. Healthy volunteers have an
increase in the pro-inflammatory cytokines IL-6, TNF-α and IL-
18 when the plasma glucose level is acutely raised by glucose
infusion while endogenous insulin secretion is blocked with
octreotide [21]. Patients with hyperglycemia on admission to
the ICU had increased levels of IL-6 and IL-10, although after
multivariate analysis only IL-6 was associated with hyperglyc-
emia [22].
Studies of cytokine responses in critically ill patients are
potentially confounded by the absence of a well-defined time
of onset and differences in the etiology and severity of the dis-
ease. Cardiac surgery is associated with the development of a
systemic inflammatory reaction with increased cytokine con-
centrations. Inflammation after cardiac surgery is believed to
be caused mainly by contact of blood with the artificial surface
of the extracorporeal circuit, and also by ischemia-reperfusion
injury, and the operative trauma [23,24]. It has been sug-
gested that the release of pro-inflammatory cytokines into the
circulation is important in the pathogenesis of post-operative
myocardial dysfunction [25-28]. We studied the effect of strict
glycemic control on the local and systemic pro-inflammatory
and anti-inflammatory cytokine balance in cardiac surgery
patients after cardiopulmonary bypass. We considered car-
diac surgery with cardiopulmonary bypass to be a suitable
clinical model of inflammation with a well-defined preset time
of onset and etiology of the insult, in contrast to other clinical
models of inflammation such as sepsis. We hypothesized that
strict glucose regulation modulates cytokine production in
these patients, leading to a shift toward a more anti-inflamma-
tory pattern [29].
Methods
Study population
We performed a randomized controlled trial in non-diabetic
patients undergoing elective coronary artery bypass grafting
(CABG). The local Institutional Review Board approved the
protocol. Written informed consent was obtained from each
patient on the day before surgery. All patients aged 18 years
or older scheduled for elective CABG were eligible for the
study. Patients were excluded if they had a history of diabetes,
fasting blood glucose levels above 100 mg/dl on the day
before surgery, myocardial infarction within 4 weeks before
surgery, cardiogenic shock or renal failure (serum creatinine
level above 1.7 mg/dl). Patients were also excluded if they had
used any medication within 4 weeks before surgery known to
modulate the inflammatory response (for example non-steroi-
dal anti-inflammatory drugs or steroids) or when there were
clinical signs of infection or inflammatory disease. The use of
low-dose salicylates was allowed. Patients undergoing off-
pump cardiac surgery were excluded. During surgery no blood
glucose concentrations were measured, and none of the
patients received insulin before admission to the ICU. Cardi-
opulmonary bypass was performed with a priming solution
containing gelatin (Gelofusine®), mannitol, albumin, NaHCO3,
CaCl2  and heparin. After weaning from cardiopulmonary
bypass, patients were given protamine to neutralize the
heparin. Heparin antagonization was identical in both groups.
Study design
Patients were randomly assigned to receive intensive or con-
ventional treatment. Assignments to the treatment groups
were made with the use of sealed envelopes. In the intensive
treatment group, patients received insulin (Actrapid HM; Novo
Nordisk, Copenhagen, Denmark) intravenously to maintain
blood glucose levels between 80 and 110 mg/dl. In the con-
ventional treatment group, insulin therapy was given when
blood glucose levels exceeded 200 mg/dl. Similarly to the trial
by van den Berghe et al. [11], treatment started immediately
on admission to the ICU. Blood glucose levels were measured
hourly and adjusted according to a nomogram based on the
study by van den Berghe et al. [11]. On admission, all patients
were infused continuously with 3.75 g of intravenous glucoseAvailable online http://ccforum.com/content/9/6/R790
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per hour. Blood samples for the measurement of systemic
cytokine concentration and drain samples from the mediastinal
cavity (local cytokine release) were taken on arrival in the ICU
and at 1, 2, 4, 8, 12, 16 and 24 hours after admission.
Cytokine analysis
Blood and samples from the tubes draining the mediastinal
cavity were immediately centrifuged for 15 minutes at 2,000 g
at 4°C, and serum and supernatants were stored at -80°C until
measurement in a single batch. Concentrations of TNF-α, IL-6
and IL-10 were measured in accordance with the manufac-
turer's instructions with a commercial sandwich-type enzyme-
linked immunosorbent assay (PeliKine; Sanquin, Amsterdam,
The Netherlands).
Statistical analysis
Power calculation was based on clinically relevant changes in
serum IL-6 levels. In previous studies a standard deviation of
14 to 16% of baseline values was found [30-32]. An insulin-
mediated decrease of 15% in IL-6 or a 15% increase in IL-10
was considered to indicate a clinically relevant change in the
pro-inflammatory and anti-inflammatory balance. With an esti-
mated SD of 15% and a significance level α of 0.05, a sample
size of nine patients per group was calculated to reach a
power of 90%. We therefore included 10 patients per group
in the present study. Changes in cytokine levels over time were
analyzed with one-way analysis of variance. Differences
between groups were analyzed with two-way analysis of vari-
ance. p < 0.05 was considered statistically significant. All data
are expressed as median (interquartile range unless otherwise
stated).
Results
Study population
A total of 20 patients were enrolled in the study. The clinical
and demographic characteristics of the two groups at rand-
omization are shown in Table 1. No differences were found
with respect to age, body mass index, duration of operation or
time on cardiopulmonary bypass. No major perioperative com-
plications were reported. APACHE (Acute Physiology and
Chronic Health Evaluation) II and Parsonnet scores were com-
parable on arrival in the ICU. Blood glucose levels on admis-
sion were slightly higher in the intensive treatment group than
in the conventional treatment group (mean ± SD 114.4 ± 15.1
versus 97.6 ± 19.8 mg/dl; p = 0.05).
No major complications occurred during the post-operative
stay in any of the patients. Post-operative time on the ventilator
and the time in the ICU were comparable in both groups
(Table 2). Both groups had similar increases in creatinine
kinase levels as a global measure of tissue damage. Equal
amounts of erythrocyte and platelet transfusions were admin-
istered in both treatment arms.
Blood glucose control
In the intensive treatment group all patients required exoge-
nous insulin, whereas in the conventionally treated group only
one patient received a low dose of insulin when blood glucose
exceeded 200 mg/dl (Figure 1a). Blood glucose levels were
significantly lower in the intensive treatment group than in the
conventional treatment group (p  < 0.003) (Figure 1b).
Hypoglycemia (defined as a blood glucose level of 40 mg/dl
or less) did not occur in any of the patients. The rise in mean
glucose levels in the placebo group, together with the escalat-
ing insulin dosage in the strict control group, suggests
increasing insulin resistance after surgery. This may be
explained by increasing catecholamine concentrations,
because the increased glucose levels coincided with tapering
of the anesthetic agents. Hemodynamic parameters such as
blood pressure, heart rate, urine production and administration
of inotropic agents were comparable between the groups
(data not shown).
TNF-α, IL-6 and IL-10 concentration in serum
Systemic concentration of TNF-α did not change statistically
during the first post-operative day (data not shown). IL-6
increased post-operatively with maximum values 2 to 4 hours
after admission (p < 0.001), followed by a gradual decline
Table 1
Baseline characteristics of patients
Characteristic Conventional treatment (n = 10) Intensive treatment (n = 10) p
Male sex, number (%) 8 (80) 10 (100)
Age, years 63.2 ± 6.6 65.2 ± 8.7 0.57
Body mass index 26.4 ± 3.1 28.4 ± 4.1 0.23
Duration of operation, minutes 181 ± 52 160 ± 34 0.31
Time on cardiopulmonary bypass, minutes 90 ± 30 83 ± 27 0.57
Blood glucose on admission, mg/dl 96.7 ± 19.6 113.3 ± 14.9 0.05
Parsonnet score 3.0 ± 4.2 5.5 ± 4.2 0.20
APACHE II score 9.2 ± 2.7 9.0 ± 3.4 0.88
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(Figure 2a). The anti-inflammatory cytokine IL-10 was
increased on admission and showed a second peak at 12
hours after admission (p = 0.002) (Figure 2b). No differences
were found between the conventional and intensive treatment
group with regard to the pattern and levels of systemic
cytokine production. The ratio of IL-6 to IL-10 increased in the
first hours with a maximum at 2 hours after admission (p <
0.001) and showed a rapid decline afterwards (Figure 2c).
TNF-α, IL-6 and IL-10 concentration in samples from the 
mediastinal cavity
Cytokines were measured in fluids from the mediastinal drains.
IL-6 levels from the mediastinal cavity increased and reached
a maximum at 8 hours after admission (p < 0.001) (Figure 3a).
Levels of IL-6 in the tubes draining the mediastinal cavity were
about 1,000-fold higher than the values measured in blood. IL-
10 concentrations showed a peak at 12 hours after admission
(p < 0.001) and were about 10 times higher in the samples
from the mediastinum than in the systemic levels (Figure 3b).
No differences were found in the mediastinal levels of TNF-α,
IL-6 and IL-10 between the treatment groups. The IL-6/IL-10
ratio had a peak at 4 hours after admission, followed by a sec-
ond rise at 12 hours after admission (p < 0.001) (Figure 3c).
Discussion
The main conclusion from the present study is that strict glu-
cose regulation does not alter cytokine concentrations in the
plasma and in the mediastinal cavity in patients after CABG.
Strict glucose control also had no effect on activation of the
terminal complement complex or leukocyte numbers (data not
shown). These results suggest that the beneficial effect of
intensive insulin therapy in patients after cardiac surgery is not
mediated by changes in cytokine balance.
The beneficial effects of strict glucose control in the study by
van den Berghe et al. [11] are supported by a study in diabetic
patients undergoing cardiac surgery in which continuous insu-
lin therapy reduced the risks of death and wound infections by
57% and 66%, respectively [33]. Multivariate logistic regres-
sion analysis has shown that the beneficial effects of strict glu-
cose control in the study by van den Berghe et al. [11] was
related mainly to an improvement in dyslipidemia [34]. How-
ever, this post hoc analysis included only patients admitted for
7 days or longer and is therefore clearly different from our
uncomplicated CABG patients. It is nevertheless possible that
the pro-inflammatory effects of increased fatty acid levels also
have a role in acute illness. Infusion of triglycerides in healthy
volunteers acutely increased NF-κB binding activity and p65
expression in circulating monocytes [35]. Activation of NF-κB
induces an inflammatory response by the increased transcrip-
tion of genes that are involved in the production of pro-inflam-
matory cytokines and adhesion molecules. Fatty acids might
therefore be involved in an acute increase in the inflammatory
response. Short-term effects of lipid modulation on morbidity
have also been shown in the Myocardial Ischemia Reduction
with Aggressive Cholesterol Lowering (MIRACL) study [36].
In this multicentre trial, patients with unstable angina pectoris
or non-Q-wave myocardial infarction treated with atorvastatine
had a lower mortality, lower incidence of recurrent ischemia,
non-fatal myocardial infarction and cardiac arrest than pla-
cebo-treated controls. Further analysis of these patients sug-
gests that the beneficial effect of this statin therapy might be
related to modulation of the cellular inflammatory response
[37].
The second important finding of our study was the compart-
mentalized cytokine production, with levels of IL-6 and IL-10
that were significantly higher in mediastinal fluid samples than
in plasma samples. Compartmentalized cytokine production
has been demonstrated in animal models [38,39] and several
clinical settings [40-42]. Our results clearly demonstrate local
production of cytokines in the mediastinal cavity after cardiac
surgery. The myocardium is a major source of cytokines. Sam-
pling of blood from the coronary sinus in patients undergoing
Table 2
Post-operative data
Event Conventional treatment (n = 10) Intensive treatment (n = 10) p
Time between end of surgery and admission to the ICU, minutes 11.4 ± 7.7 18.4 ± 9.1 0.10
Time in ICU, hours 20.3 ± 2.5 22.1 ± 1.8 0.09
Time on ventilator, hours 9.8 ± 4.6 11.2 ± 6.6 0.65
Creatinine kinase, U/l
On admission 342 ± 371 273 ± 171 0.60
At 16 hours after admission 649 ± 483 684 ± 499 0.88
Erythrocyte transfusion, units 1.67 ± 1.5 1.10 ± 0.88 0.32
Platelet transfusion, units 0.63 ± 0.74 0.33 ± 0.50 0.35
Values are means ± SD. ICU, intensive care unit.Available online http://ccforum.com/content/9/6/R790
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CABG showed increased levels of TNF-α and IL-6 than in
serum [43,44]. In patients with signs of myocardial necrosis
the inflammatory response originates from the myocardium
itself [45,46].
Compartmentalized cytokine production is also suggested in a
study in which elective percutaneous coronary intervention
with and without cardiopulmonary bypass and cardiopulmo-
nary bypass supported CABG were compared [47]. Patients
undergoing CABG had much higher IL-6 levels than those
undergoing the other interventions, suggesting that the local
surgical trauma contributes more to the inflammatory response
than the systemic reaction to cardiopulmonary bypass. Our
data, in concordance with these studies, suggest that the
operative trauma to the myocardium and its surrounding tis-
sues is the major source of cytokine production after cardiac
surgery. It is unlikely that the systemic inflammatory response
syndrome response elicited by the extracorporal bypass has a
major role because IL-6 and IL-10 production in the mediasti-
nal cavity exceeded systemic production 1,000-fold and 10-
fold, respectively. The local operative trauma and possibly
ischemia-reperfusion injury is a more likely explanation for the
higher local cytokine concentrations. These results also imply
Figure 1
Insulin dosage and glucose concentration are significantly different  between the treatment groups Insulin dosage and glucose concentration are significantly different 
between the treatment groups. Insulin dosage per hour (a) and glucose 
concentration in serum (b) in the intensive and conventional treatment 
group after admission to the intensive care unit. Points are median 
values.
Figure 2
Systemic cytokine concentrations are comparable between the treat- ment groups Systemic cytokine concentrations are comparable between the treat-
ment groups. Concentration of IL-6 (a) and IL-10 (b) at different time 
points after admission to the intensive care unit. (c) The ratio of IL-6 to 
IL-10 in serum is expressed as arbitrary units. No significant differences 
are found between both treatment groups. Points are median values.Critical Care    Vol 9 No 6    Hoedemaekers et al.
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that studies trying to unravel the mechanisms underlying the
effect of glucose and insulin on inflammatory processes
should preferably take place in the compartment of interest. In
this context it would be interesting to study cytokine concen-
trations in the coronary sinus under various conditions.
Our results are in conflict with several other studies showing
that hyperglycemia increases the production of pro-inflamma-
tory cytokines [21,22]. Although differences between glucose
levels in the two treatment groups were highly significant,
hyperglycemia in the conventionally treated patients was
milder than in several other studies and this might have
resulted in an impaired trigger for the immune system to
change the balance. As a result of modern peri-operative tech-
niques, the systemic inflammatory response syndrome
induced by surgery and cardiopulmonary bypass was relatively
mild, as is reflected by relatively low APACHE II scores in both
groups. In the study by van den Berghe et al. [11] the largest
reduction in mortality was found in patients with multiple organ
failure and sepsis. In septic patients the systemic inflammatory
response results in very high concentrations of pro-inflamma-
tory cytokines. It might be that under these circumstances
strict glucose control can shift the cytokine balance toward a
more anti-inflammatory pattern.
One might speculate that the timing, duration and dosage of
insulin could have influenced the results of this study. Institut-
ing insulin therapy before admission to the ICU would proba-
bly not have changed the cytokine balance, because median
blood glucose levels on admission were within the target
range of insulin treatment, and blood glucose levels became
different between the groups only after 4 hours of treatment. It
is unlikely that insulin treatment beyond the first 24 hours
would have influenced the cytokine balance significantly,
because after the first 18 hours glucose levels started to nor-
malize in the control group, and cytokine concentrations are
known to decline rapidly after the first day of surgery. Because
the beneficial effects of post-operative glucose control are
most probably related to lowered blood glucose levels rather
than the insulin dose, it is not to be expected that increasing
levels of insulin will change the inflammatory response [12,13].
Conclusion
Strict glucose regulation in acute and critically ill diabetic and
non-diabetic patients reduces morbidity and mortality in sev-
eral clinical settings. The exact mechanisms underlying these
acute beneficial effects of intensive insulin therapy remain
unknown. Our study shows that a change in balance between
pro-inflammatory and anti-inflammatory cytokines does not
explain the beneficial effects seen in ICU patients after cardiac
surgery. The importance of a compartmentalized cytokine pro-
duction implicates that studies that focus on systemic effects
of glucose and insulin should be interpreted with caution.
Figure 3
Cytokine production is highly compartmentalized Cytokine production is highly compartmentalized. Concentration of IL-6 
(a) and IL-10 (b) in mediastinal fluid at different time points after admis-
sion to the intensive care unit. (c) The ratio of IL-6 to IL-10 in mediasti-
nal fluid is expressed as arbitrary units. No significant differences are 
found between both treatment groups. IL-6 and IL-10 levels are signifi-
cantly higher in the mediastinal fluid samples than in plasma samples, 
indicating local production. Points are median values.Available online http://ccforum.com/content/9/6/R790
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